Profile: MedImmune, LLC. provides medicines to patients, new medical options for physicians and rewarding careers to employees. We focus on the areas of infectious diseases, cancer and inflammatory diseases. Our Synagis® is the first monoclonal antibody successfully developed to combat an infectious disease that is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease. Our FluMist® (Influenza Virus Vaccine Live, Intranasal) is a nasal spray flu vaccine which helps to prevent influenza and is indicated for the active immunization of eligible individuals from two to 49 years of age against influenza disease caused by influenza virus subtypes A & type B contained in the vaccine. The FluMist is different from the flu shot in that it uses live, attenuated or weakened viruses within the vaccine to help stimulate an immune response that is designed to closely resemble the body's natural response to an influenza infection.